 is a potentially lethal form of the disease. Here’s what you should know, from diagnosis to treatment.){kind=link}
Most people with clinical trials, the newest drugs for nmCRPC can delay the spread of prostate cancer for an average of up to nearly 3 1/2 years. People who took these drugs lived up to an average of 14 months longer than those who took a placebo.
The average person whose CRPC has spread will live less than 2 years with mCRPC. However, new treatments are starting to lengthen that amount of time, so there is hope that people with this condition will be able to live longer.
Does CRPC Affect Different Ethnic/Racial Groups Differently?
Non-Hispanic Black people are much more likely to get prostate cancer than those of any other race or ethnicity. Prostate cancer rates are lowest among non-Hispanic Asian Americans. Black people also are more likely than non-Black people to be diagnosed with advanced prostate cancer. But in treatment, Black people have at least similar outcomes compared to non-Black people. Researchers don’t fully understand the reasons for these differences.